Supplementary Table S1 from Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia

In our limited experience with Mog monotherapy for relapsed/refractory ATL (including the case shown in Fig.S3), excluding patients who received allo-HSCT and combined therapy with Mog and intensified chemotherapy mSLG15(ref.32) had shown that lymphocyte counts during Mog monotherapy in patients for whom the treatment failed to suppress disease progression (failure n=4) tended to be lower than that when Mog monotherapy successfully controlled disease (successful n=2). Total time points when cell counts were measured were shown, respectively. Data indicated as mean {plus minus} SD, respectively.